About US
Contact us
-
2012’PhexTour pharmaceutical excipients application technology national tour seminar ——the fifth Jinan station has come to an end2012 PhexTour pharmaceutical excipients application technology national tour seminar the fifth station-Jinan, on July 25th, in Jinan Minjuyihe international hotel has come to an end. Nearly 26 local2012/8/3
-
Bristol-Myers hep C trial hits the skids on safety concernsIn January, Bristol-Myers Squibb ($BMY) paid $2.5 billion for Inhibitex, jazzed by the prospects for its hepatitis C drug candidate. Now, 7 months later, that drug is in deep trouble. The company stop2012/8/3
-
Teva, Takeda boost profits as Valeant swings to lossTeva Pharmaceutical Industries ($TEVA) is the biggest fish in today's earnings pond. The generics giant--which now has a sizable footprint in branded drugs thanks to its Cephalon buyout--met expectati2012/8/3
-
U.K. drug spending down, scripts up on 'patent dividend'Want a statistical representation of the patent cliff's decidedly mixed blessings? The U.K. just released its latest report on drug spending. The gist is, costs are down but prescription numbers are u2012/8/2
-
Can retooled Pfizer deliver on R&D promises?Pfizer ($PFE) CEO Ian Read is long on promises of a sunny R&D future. But its near-term pipeline offers iffy benefits, and Read hasn't clearly outlined his approach to juggling internal research w2012/8/2
-
FDA nixes new gout use for Regeneron's ArcalystThe FDA dashed Regeneron's ($REGN) immediate hopes for a vast expansion of its anti-inflammatory drug Arcalyst. The drugmaker had been aiming to market Arcalyst to prevent gout flare-ups, but the agen2012/8/1
-
Bayer profits hit by $500M charge for Yaz/Yasmin lawsuitsBayer set aside $500 million to cover litigation over the Yaz and Yasmin birth control pills, after FDA added blood-clot warnings to their labels in April. Meanwhile, the company's second-quarter numb2012/8/1
-
Europeans notch approvals for Vertex, Novartis drugsThe European Commission has opened the gates for another round of drug launches. Regulators gave their final blessing to Vertex Pharmaceuticals' ($VRTX) cystic fibrosis treatment Kalydeco, Almirall's2012/7/31
-
SFDA issues the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012On July 20, 2012, the State Food and Drug Administration (SFDA) issued the Second Summary of Announcements of Illegal Drug, Medical Device, and Health Food Advertisements in 2012.2012/7/31
-
Regeneron expanding as its sees higher sales with EyleaRegeneron Pharmaceuticals ($REGN) is expecting a surge of sales of its eye drug Eylea and is expanding production in preparation. The New York company says it is plowing $75 million into its plant in2012/7/30